144 related articles for article (PubMed ID: 36354295)
21. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update.
Teschke R; Vongdala N; Quan NV; Quy TN; Xuan TD
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638760
[TBL] [Abstract][Full Text] [Related]
22. miR-511-3p promotes hepatic sinusoidal obstruction syndrome by activating hedgehog pathway via targeting Ptch1.
Yang L; Xu X; Chen Z; Zhang Y; Chen H; Wang X
Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(3):G344-G354. PubMed ID: 34287088
[TBL] [Abstract][Full Text] [Related]
23. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang X; Zhang W; Zhang M; Zhang F; Xiao J; Yin Q; Han H; Li T; Lin G; Zhuge Y
Hepatol Int; 2022 Jun; 16(3):669-679. PubMed ID: 35023026
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
Li YS; Bao J; Xu Y; Wang TL
Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
[No Abstract] [Full Text] [Related]
25. The involvement of Nrf2 antioxidant signalling pathway in the protection of monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats by (+)-catechin hydrate.
Jing X; Zhang J; Huang Z; Sheng Y; Ji L
Free Radic Res; 2018 Apr; 52(4):402-414. PubMed ID: 29458270
[TBL] [Abstract][Full Text] [Related]
26. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
27. Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Huang Q; Zhang Q; Xu H; Zu M; Xiao J; Shen B
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):445-452. PubMed ID: 36719828
[TBL] [Abstract][Full Text] [Related]
28. A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang W; Chen Y; Yin Y; Wang X; Ye X; Jiang K; Zhang Y; Zhang J; Zhang W; Zhuge Y; Chen L; Peng C; Xiong A; Yang L; Wang Z
Arch Toxicol; 2022 Jul; 96(7):2003-2019. PubMed ID: 35357534
[TBL] [Abstract][Full Text] [Related]
29. Phosphodiesterase III inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space.
Miyata T; Tajima H; Hirata M; Nakanuma SI; Makino I; Hayashi H; Oyama K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Iseki S; Harada SI; Wakayama T; Ohta T
J Gastroenterol Hepatol; 2018 Apr; 33(4):950-957. PubMed ID: 28960464
[TBL] [Abstract][Full Text] [Related]
30. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
31. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
32. Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids.
Du X; Liu Z; Yu H; Wang Y; Zou Z; Wei H; Liang J; Yang D; Liu Y; Zhang J; Pan CQ
Medicine (Baltimore); 2023 Aug; 102(32):e34698. PubMed ID: 37565875
[TBL] [Abstract][Full Text] [Related]
33. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats.
Li YH; Tai WC; Xue JY; Wong WY; Lu C; Ruan JQ; Li N; Wan TF; Chan WY; Hsiao WL; Lin G
Chem Res Toxicol; 2015 Sep; 28(9):1715-27. PubMed ID: 26280871
[TBL] [Abstract][Full Text] [Related]
34. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
Lin G; Wang JY; Li N; Li M; Gao H; Ji Y; Zhang F; Wang H; Zhou Y; Ye Y; Xu HX; Zheng J
J Hepatol; 2011 Apr; 54(4):666-73. PubMed ID: 21146894
[TBL] [Abstract][Full Text] [Related]
35. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats.
Chen X; Ma J; He Y; Xue J; Song Z; Xu Q; Lin G
Phytomedicine; 2021 Aug; 89():153595. PubMed ID: 34153877
[TBL] [Abstract][Full Text] [Related]
36. Hepatic sinusoidal obstruction syndrome caused by the ingestion of
Cen P; Ding J; Jin J
J Int Med Res; 2021 Apr; 49(4):300060520980649. PubMed ID: 33845617
[TBL] [Abstract][Full Text] [Related]
37. Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report.
Zheng Q; Zhang H
Medicine (Baltimore); 2024 Mar; 103(11):e37341. PubMed ID: 38489699
[TBL] [Abstract][Full Text] [Related]
38. Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring.
Li R; Li L; Cai Z; Chen J; Zhang H; Zhao S; Tu J; Sun C; Jin Y; Zhang M; Zhang F; Zhang W; Yin Q; Xu H; Han H; Li T; Zhuge Y; Xiao J
Dig Liver Dis; 2024 Jul; 56(7):1220-1228. PubMed ID: 38151450
[TBL] [Abstract][Full Text] [Related]
39. Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid.
Tu H; Li M; Chen Z; Zhao J; Wang H; Qian J; Wei C; Yang Y; Zhu Y; Zuo L
J Clin Lab Anal; 2022 Feb; 36(2):e24240. PubMed ID: 35034375
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9.
Nakamura K; Hatano E; Narita M; Miyagawa-Hayashino A; Koyama Y; Nagata H; Iwaisako K; Taura K; Uemoto S
J Hepatol; 2012 Nov; 57(5):1037-43. PubMed ID: 22796153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
